| Article Access Statistics|
| Viewed||1792 |
| Printed||55 |
| Emailed||0 |
| PDF Downloaded||114 |
| Comments ||[Add] |
Click on image for details.
| SHORT COMMUNICATION
|Year : 2018 | Volume
| Issue : 4 | Page : 204-207
Cefixime-associated acute generalized exanthematous pustulosis: Rare cases in India
Vipin Kumar1, Vivekanandan Kalaiselvan1, A Pramod Kumar1, Archana Saurabh1, Prasad Thota2, Shabir Sidhu2, Bikash Medhi3
1 National Coordination Centre-Pharmacovigilance Programme of India, Indian Pharmacopoeia Commission, Ghaziabad, Uttar Pradesh, India
2 Department of Life Sciences, I. K. Gujral Punjab Technical University, Kapurthala, Punjab, India
3 Department of Pharmacology, Postgraduate Institute of Medical Education and Research, Chandigarh, India
BACKGROUND: Cefixime is a widely used third-generation cephalosporin schedule H1 drug, which is prescribed for the treatment of otitis media, respiratory tract infections, and uncomplicated urinary tract infections and is effective against infections caused by Enterobacteriaceae and Haemophilus influenzae species in India. The National Coordination Centre (NCC)-Pharmacovigilance Programme of India (PvPI), Indian Pharmacopoeia Commission (IPC), has received rare individual case safety reports (ICSRs) for acute generalized exanthematous pustulosis (AGEP) associated with the use of cefixime.
MATERIALS AND METHODS: IPC, NCC-PvPI also acts as a national collaborating center for pharmacovigilance activities under the aegis of Ministry of Health and Family Welfare, Government of India; moreover, it is a member country in global pharmacovigilance system, World Health Organization-Uppsala Monitoring Centre, Sweden. There are more than 250 government/corporate medical colleges and hospitals acting as regional adverse drug reaction monitoring centers, actively functioning under PvPI. Furthermore, various stakeholders including consumers and pharmaceutical industries also play a significant contribution. NCC-PvPI receives spontaneous ICSRs from various stakeholders.
RESULTS: NCC-PvPI, IPC has received a total of four spontaneous ICSRs for cefixime-induced AGEP. After clinical evaluation of reported ICSRs, a strong causal relationship was established between AGEP and cefixime and was supported by published literature and histopathological examination of skin. Based on the statistics with positive information component (IC025 Value: 0.17) and proportionality relative risk (PRR:3.4), PvPI considered cefixime-associated AGEP may be a potential signal.
CONCLUSION: Hence, initially, AEGP is considered by PvPI as drug safety alert in July 2016. Therefore, to enhance the safety of population in rational usage of medication, as a result, there is a need for physicians and health-care professionals to sensitize about serious adverse reaction while prescribing the cefixime as signal in India.
Mrs. Archana Saurabh
Pharmacovigilance Programme of India, Indian Pharmacopoeia Commission, Sector 23, Raj Nagar, Ghaziabad - 201 002, Uttar Pradesh
Source of Support: None, Conflict of Interest: None
[FULL TEXT] [PDF]*